Halda Therapeutics, a biotechnology company focused on developing RIPTAC (Regulated Induced Proximity Targeting Chimeras) therapeutics, has announced the appointment of Christian Schade as President and Chief Executive Officer. Schade, who also joins the Board of Directors, brings over 20 years of experience in the pharmaceutical and biotechnology industries to the role.
Schade's appointment comes as Halda Therapeutics prepares to advance its lead RIPTAC program into clinical trials. The company's first RIPTAC therapeutic is slated to begin clinical trials in the first half of 2025, targeting metastatic, castration-resistant prostate cancer (mCRPC).
Leadership Transition and Strategic Focus
Tim Shannon, Chairman of Halda’s Board of Directors and General Partner of Canaan Partners, expressed confidence in Schade's ability to lead the company. "His strong track record building and leading biotech companies is ideally suited to Halda’s next stage of evolution to a clinical-stage cancer company," Shannon stated.
Schade himself conveyed enthusiasm for joining Halda, stating, "This is a time of strong momentum for the company, particularly as the first RIPTAC therapeutic is on track to begin clinical trials in the first half of 2025. There are many exciting prospects ahead to expand Halda’s pipeline and explore business opportunities, as we leverage the RIPTAC platform to develop targeted oral cancer therapies to improve outcomes for cancer patients."
Schade's Extensive Background
Prior to joining Halda, Schade was a Growth Partner at Flagship Pioneering. He also served as President and CEO of Aprea Therapeutics, leading the company through its IPO in 2019. His experience also includes executive leadership positions at Novira, Omthera Pharmaceuticals, and Medarex.
Halda's RIPTAC Technology
Halda Therapeutics' RIPTAC platform, developed by Professor Craig Crews from Yale University, employs a novel "hold and kill" mechanism for precision cancer treatment. This approach is designed to overcome cancer's ability to develop resistance mechanisms, a common limitation of current precision oncology medicines. The company's lead programs target prostate and breast cancer, with additional programs in the pipeline to address unmet medical needs in cancer.
